
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc is exhibiting strong financial performance and growth potential, evidenced by a notable 56% increase in spending during 3Q25, which is anticipated to enhance awareness and drive procedures. The company's advertising expense rose by 34% year-over-year in 2023, reflecting a commitment to expanding its market presence, while management's guidance for 2025 indicates a significant increase in direct-to-consumer spending, alongside disciplined cost management measures. Additionally, Inspire is expected to increase its average selling price (ASP) beginning in 2026, which, combined with improved reimbursement prospects, is likely to boost both volume and revenue significantly.
Bears say
Inspire Medical Systems Inc. has experienced a deceleration in advertising expenditures, with a projected 2024 ad expense decrease of 5% year-over-year, signaling potential difficulties in marketing effectiveness. The launch of a critical new product, the Inspire 5, has encountered unforeseen challenges, prompting management to revise revenue and EPS expectations downwards, which negatively affects the stock valuation. Additionally, the company has made significant cuts to operational expenses, particularly in research and development, raising concerns about its ability to sustain growth and innovation in a competitive market.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares